Gland Pharma To Spend 400 Cr To Increase Capacity In Hyderabad
Gland Pharma is set to invest over 400 crores to expand the capabilities of its current facility located in Genome Valley.
The expansion is aimed at increasing the production of biologicals, biosimilars, antibodies, and recombinant insulin. The company plans to hire over 500 people from the surrounding areas for the expanded facility.
Earlier this year, the Hyderabad-based pharmaceutical company opened a biopharmaceutical facility worth Rs 300 crore to produce vaccines, biologicals, biosimilars, antibodies, and other products. The facility has already hired 200 new employees.
The new site will be constructed in accordance with Good Manufacturing Practices (GMP) standards for the relevant product lines and will adhere to all applicable national and international regulations for manufacturing biological products.
The announcement was made following a meeting between Gland Pharma’s Srinivas Sadu and Telangana Industries Minister, KT Rama Rao.
“This project investment is estimated to be around 400 crore and expected to generate employment for about 500 personnel,” said Srinivas Sadu in a press release.
“The expansion will focus on advanced areas such as biologicals, biosimilars, antibodies, and recombinant insulin, all of which are areas where the state is focused on building capabilities and solidifying our leadership position,” said K.T. Rama Rao.
For more than 40 years, Gland Pharma Ltd has been offering high-quality products for consumers’ healthcare.
